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Abstract
Management of Crohn's disease has traditionally placed high value on subjective symptom
assessment; however, it is increasingly appreciated that patient symptoms and objective
parameters of inflammation can be disconnected. Therefore, strategies that objectivelyxcHangE on the ADvances in Inflammatory Bowel Disease; CD, Crohn's disease; CDAI, Crohn's Disease
ndoscopic Index of Severity; CRP, C-reactive protein; CT, computed tomography; GI, gastrointestinal;
mmatory bowel disease; IBDQ, Inflammatory Bowel Disease Questionnaire; ISC, International Steering
maging; QOL, quality of life; SBCE, small-bowel capsule endoscopy; SBFT, small-bowel follow-through;
rohn's Disease; TNF, tumour necrosis factor.
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monitor inflammatory activity should be utilised throughout the disease course to optimise
patient management. Initially, a thorough assessment of the severity, location and extent of
disease is needed to ensure a correct diagnosis, identify any complications, help assess prognosis
and select appropriate therapy. During follow-up, clinical decision-making should be driven by
disease activity monitoring, with the aim of optimising treatment for tight disease control.
However, few data exist to guide the choice of monitoring tools and the frequency of their use.
Furthermore, adaption ofmonitoring strategies for symptomatic, asymptomatic and post-operative
patients has not been well defined. The Annual excHangE on the ADvances in Inflammatory Bowel
Disease (IBD Ahead) 2011 educational programme, which included approximately 600 gastroenter-
ologists from 36 countries, has developed practice recommendations for the optimal monitoring
of Crohn's disease based on evidence and/or expert opinion. These recommendations address
the need to incorporate different modalities of disease assessment (symptom and endoscopic
assessment, measurement of biomarkers of inflammatory activity and cross-sectional imaging) into
robust monitoring. Furthermore, the importance of measuring and recording parameters in a
standardised fashion to enable longitudinal evaluation of disease activity is highlighted.
© 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.Contents
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51. Introduction
Crohn's disease (CD) is a chronic inflammatory bowel disease
(IBD) characterised by periods of symptomatic relapse and
remission. Inflammation often persists in the absence of
gastrointestinal (GI) symptoms1 and may lead to progressive
bowel damage and complications such as fistulae, abscesses
and strictures. In many patients, impaired bowel function
ultimately leads to impaired quality of life (QOL) and
disability.2 Therefore, treatment goals in CD are evolving
beyondmere control of symptoms towards targeting sustained
control of GI inflammation, with the ultimate objectives of
preventing bowel damage, reducing long-term disability and
maintaining QOL.3,4 As such, assessment of objective mea-
sures of inflammation is an increasingly important part of the
management approach in a CD patient. Thorough assessment
of disease activity and extent at presentation is needed
to ensure a correct diagnosis of IBD (versus non-IBD) and of
CD (versus ulcerative colitis), avoid delay in diagnosis, identifycomplications and help assess prognosis. This information
enables appropriate treatment and increases the likelihood
of achieving management goals.5–7 During follow-up, clinical
decision-making is increasingly being driven by the findings of
continued monitoring (for objective evidence of inflamma-
tion), with the aim of optimising treatment for tight disease
control.8
Despite the potential benefits of longitudinal monitoring
in CD, there are several unanswered questions around
implementing this model in practice: Which monitoring
tools should be used? When should they be used? How should
the monitoring strategy differ in different patient scenarios?
Given the uncertainties around these issues, practice
recommendations were developed based on the best pub-
lished evidence available and/or expert opinion as part of
the IBD Ahead 2011 educational programme, which involved
approximately 600 gastroenterologists from 36 countries
(see Appendix A). Here we provide a physician's perspective
on a thorough and appropriate baseline assessment, and the
Box 1. Symptom-based and endoscopic scoring sys-
tems in Crohn's disease.
Symptom-based scoring systems
Crohn's Disease Activity Index (CDAI)9
• Consists of eight factors, including frequency of soft/
liquid stools, severity of abdominal pain, general well-
being, presence of extraintestinal manifestations,
requirement for antidiarrhoeal medication, presence
of an abdominal mass, haematocrit level and percent-
age deviation from standard body weight.
Harvey–Bradshaw Index (HBI)10
• Asimple index restricted to clinical parameters of general
well-being, abdominal pain, frequency of liquid stools,
presence of an abdominal mass and extraintestinal
manifestations.
Inflammatory Bowel Disease Questionnaire
(IBDQ)11,12
• Incorporates social, systemic and emotional symptoms
together with bowel-related symptoms into an activity
index.
• Shown to be valid and reliable across several different
language and culture settings.110
• May have a stronger correlation with utility than the
CDAI.111
• A shortened version of the IBDQ has also been
developed and is considered able to detect meaningful
clinical changes in health-related quality of life.112
Endoscopic scoring systems
Crohn's Disease Endoscopic Index of Severity (CDEIS)16
• Five segments are individually scored based on the
presence of deep or superficial ulcerations and the
extent of surface involved by disease or ulcerations.
The presence of stenosis is also scored.
• Scores range from 0–44, with a higher score indicting
greater severity.
Simple Endoscopic Score for Crohn's Disease
(SES-CD)17
• Five segments are individually scored based on the
presence and size of ulcers, extent of the ulcerated
surface, extent of the affected surface and the presence
and type of narrowings.
• Scores range from 0–56, with a higher score indicting
greater severity.
• SES-CD has been shown to correlate strongly with the
CDEIS and also with symptom-related measures.113
Rutgeerts score for post-operative recurrence18
• Lesions at the neoterminal ileum and ileocolonic
anastomosis are explored and scored on a scale from i0
to i4.
• Score has been shown to predict the duration of
symptom-free survival.18
655Optimising monitoring in Crohn’s diseasesubsequent optimised monitoring in symptomatic, asymp-
tomatic and post-operative CD patients.
2. Monitoring tools for CD
In CD, disease activity can be evaluated by symptom assess-
ment, endoscopic assessment, measurement of biomarkers and
cross-sectional imaging.
2.1. Symptom-based monitoring
Several scoring systems have been developed to evaluate
the severity of symptoms in patients with CD (Box 1). The
Crohn's Disease Activity Index (CDAI)9 and the Harvey–
Bradshaw Index (HBI)10 evaluate bowel-related symptoms,
complications and general well-being, while the Inflamma-
tory Bowel Disease Questionnaire (IBDQ)11,12 incorporates
social, systemic and emotional symptoms together with
bowel-related symptoms. These indices are routinely used in
clinical trials to assess drug treatments and are becoming
more commonly used in clinical practice, as the threshold
for reimbursement for biologic treatment in some countries
is assessed using symptom-based scoring. Using indices that
are responsive to changes in disease severity has value in
allowing consistent longitudinal monitoring of symptoms;
however, it must be noted that some items of the CDAI are
open to subjective interpretation (e.g. “general well-being”
or “severity of abdominal pain”).13 Subjectivity may also
impact on the ability of the IBDQ to accurately assess bowel
or systemic symptoms14; nevertheless, it has shown reliabil-
ity and validity in assessing QOL domains in CD.12,15
2.2. Endoscopy
Mucosal healing has emerged as an important goal in CD
management. Several endoscopic scoring systems have been
developed to facilitate consistent and reproducible assess-
ment of the severity of mucosal damage at predefined sites
(Box 1).16–18 These instruments assess both disease extent
and severity, and are now routinely used in clinical trials.
However, lack of a single standardised endoscopy score and
broadly accepted or validated thresholds for active disease
and endoscopic remission, together with insufficient knowl-
edge of the natural history of different lesions, have pre-
cluded their widespread use in routine clinical practice. In
addition, endoscopy is invasive, costly, time-consuming and
disliked by patients; therefore, it is performed only to
inform critical treatment decisions.
2.3. Laboratory-based monitoring
Multiple biomarkers that reflect the presence of active
inflammation have been identified; however, very few have
proven to be clinically useful in IBD. C-reactive protein (CRP),
an acute-phase reactant that correlates moderately well with
clinical, endoscopic, histologic, and radiographic disease
activity, is inexpensive to measure with a readily available
blood test.19–25 Faecal calprotectin and lactoferrin are
heat-stable granulocyte-derived proteins that are relatively
inexpensive, non-invasive, and have been studied extensivelyin IBD.26–30 Both biomarkers can be assayed directly in stool
using ELISA-based testing. They have been shown to correlate
significantly with colonic endoscopic score and histology in
656 P. Papay et al.patients with ileocolonic or colonic disease, although not with
ileal endoscopic score and histological findings in ileal
disease.31,32 However, there are limitations to using CRP and
stool biomarkers tomonitor CD activity as they are not specific
for IBD. Furthermore, no validated thresholds that define
active disease and biochemical remission exist.
2.4. Cross-sectional imaging
Cross-sectional imaging tools are important in CD for
establishing disease severity and extent, as well as ruling
out complications. As such, they can aid diagnosis and guide
therapeutic strategies. Cross-sectional imaging may com-
plement endoscopic assessment by providing additional
insight into disease activity, allowing assessment of the
entire small bowel and excluding complications such as
stenosis or penetrating disease. Various cross-sectional
imaging tools are available (Table 1), including magnetic
resonance imaging (MRI), ultrasonography and computed
tomography (CT). MRI is considered one of the reference
standards in the diagnostic assessment of CD.33 It allows high
soft-tissue contrast and has static, dynamic and direct
multiplanar imaging capabilities. MRI accuracy is optimised
with the use of luminal and intravenous contrast and can be
used to evaluate the activity of small- and large-bowel
disease and to document complications including stenosis,
fistula and abscess. Pelvic MRI is the modality of choice for
imaging the pelvis and perianal area. Ultrasonography is a
relatively accessible tool for an urgent broad assessment
of disease activity and for exclusion of complications, with
high reproducibility and low inter-observer variability.33,34
It is minimally invasive and an ionising radiation-free tool.
Contrast-enhanced ultrasonography allows microvascular
imaging of the bowel and quantitative differentiation be-
tween inflamed and normal bowel segments based on their
different diffusion pattern35; however, it does not allow
differentiation between predominantly inflammatory or
fibrotic stenosis.36 CT enterography combines CT techniques
with oral and intravenous contrast.37 It has similar advan-
tages to MR enterography; however, ionising radiation
exposure limits its use to emergency situations.
3. Monitoring in different patient scenarios
Table 2 provides a summary of the final statements from the
IBD Ahead 2011 programme. These statements, together with
the level of supporting evidence, are provided in Appendix A.
3.1. At diagnosis
Careful evaluation of disease characteristics at baseline is
essential for differential diagnosis, establishing the extent,
severity and behaviour of disease, objectively evaluating
inflammation and ruling out complications. Initial findings
inform both prognostic assessment and treatment decisions
and also provide a baseline for future follow-up. For these
reasons, care should be taken to use standardised tools
accurately. It is imperative that a complete assessment be
made at diagnosis and, where resources allow, we propose
that all four assessment modalities – symptom assessment,endoscopic assessment, laboratory markers and cross-sectional
imaging – are used. This will serve as a baseline from which
disease evolution and management success can be evaluated.
In clinical practice, gastroenterologists typically rely on
their global clinical judgement for symptom evaluation;
however, use of a standardised tool (see Box 1) that is re-
sponsive to changes in disease severity from diagnosis on-
wards might allow greater objective and valid assessment.
We encourage use of the HBI as it is simple to administer,
amenable to same-day clinic visits, relatively well correlat-
ed to CDAI scores,10,38 and has a higher objective component
than the IBDQ.
Endoscopy should be performed in all patients with
symptoms suggestive of IBD to enable diagnosis and assess
the location, extent and severity of mucosal lesions. We
strongly suggest using precise and standardised descriptions
of endoscopic lesions, including type, location, depth and
extent. Scoring of severity may be achieved with the Crohn's
Disease Endoscopic Index of Severity (CDEIS)16 or Simple
Endoscopic Score for Crohn's Disease (SES-CD),17 although
use of these tools may not be practical in routine clinical
practice. Ileocolonoscopy examining the terminal ileum and
all colonic segments, with precise description of lesions,
biopsy and subsequent histological examination, is needed
to support the diagnosis, as well as to differentiate IBD from
other causes of colitis, and CD from ulcerative colitis.39–41
Biopsies should be taken from endoscopically affected and
non-affected areas to histologically document the existence
of spare segments between areas of inflammation. When
biopsy of abnormal areas is not within the reach of the stan-
dard gastroscope or ileocolonoscope, then single- or double-
balloon enteroscopy should be considered.22,23 Upper GI
endoscopy/biopsy may be useful, particularly in paediatric
patients and in adult patients with upper GI symptoms. In a
patient in whom there is high clinical suspicion of CD but
inconclusive ileocolonoscopy, gastroscopy, cross-sectional
imaging and small-bowel capsule endoscopy (SBCE) may aid
diagnosis and should be considered.42
In our opinion routine blood tests, (complete blood count,
liver profile, albumin, iron studies, renal function, vitamin
B12 and assessment of CRP and stool biomarkers) should
be conducted in all patients to establish baseline values
for future comparison. Initial assessment of CRP has an im-
portant diagnostic and prognostic role19,23,43–45; however, it
should be noted that approximately 20% of patients with
active CD may have normal CRP levels.46 While the sen-
sitivity and specificity of the CRP test are not high enough to
allow differentiation from other disorders, thus precluding
its use as an IBD screening tool,47 faecal calprotectin and
faecal lactoferrin can help differentiate suspected IBD from
IBS or functional disease.24,28,30,31,48–50 A meta-analysis of
13 studies found that faecal calprotectin had a pooled
sensitivity of 93% and pooled specificity of 96% to diagnose
IBD in adults; corresponding sensitivity and specificity in
children and teenagers were 92% and 76%, respectively.28 A
larger review, including 30 studies, found that faecal
calprotectin had a sensitivity of 95% and specificity of 91%
for differentiating IBD from non-IBD diagnoses.30 In addition,
the diagnostic precision of faecal calprotectin was greater
with a cut-off of 100 μg/g compared with 50 μg/g.
We propose that cross-sectional imaging is needed in all
patients at diagnosis to assess the extent and severity of
Table 1 Pooled analysis of use of ultrasonography, CT and MRI for the diagnosis, assessment of activity and abdominal
complications of CT.51
Per-patient
sensitivity
(95% CI)
Per-patient
specificity
(95% CI)
Important findings
At diagnosis
Ultrasonography vs endoscopy 85% (83–87) 98% (95–99) Factors associated with a diagnosis of CD
• Bowel wall thickness ≥4mm
• Decreased compressibility of thickened bowel
walls, narrowing of the lumen, conglomeration
of loops and extramural lesions such as fistulas
or abscesses
Factors influencing ultrasound accuracy
• Disease location and activity (highest sensitivity
for anatomic areas easily accessible by
ultrasound, such as terminal ileum and left colon)
• Differences in ultrasound unit resolution, cut-off
unit for bowel wall thickness, experience
of ultrasonographers
MRI vs endoscopy 78% (67–84)114–117 85% (76–90) Factors associated with a diagnosis of CD
• Bowel wall thickness
• Wall enhancement after injection of MRI contrast
• Presence of oedema
Factors influencing MRI accuracy
• Distension of the bowel and use of a luminal
contrast may affect accuracy of detecting
changes associated with active disease
Assessment of disease extent
Ultrasonography vs other imaging
techniques/endoscopy/surgery
86% (83–88%) 94% (93–95%) • Bowel hydrosonography increases sensitivity for
detection of segments with active disease
• Hydrocolonic sonography provides high accuracy
for assessing colonic lesions
MRI vs other imaging techniques/
endoscopy/surgery (small bowel)
74% (68–80) 91 (86–95) • May be more useful than ultrasound for
assessment of jejunal and ileal lesions
CT vs ileocolonoscopy/surgery 88% 88% • Sensitivity for detection of lesions in colonic
segments was significantly lower than for
the ileum
Assessment of disease activity
Ultrasonography vs other imaging
techniques/endoscopy/surgery
85% (79–89) 91% (87–95) • Wall thickness and angiographic vascularisation
pattern are useful for detection of active disease
• Sensitivities and specificities of conventional,
Doppler and contrast-enhanced ultrasound are
very similar
MRI vs other imaging techniques/
endoscopy/surgery (terminal
ileum and/or colon)
80% (77–83) 82% (78–85) • MRI may achieve a similar sensitivity to ultrasound
if adequate luminal distension is achieved
CT vs other imaging techniques/
endoscopy/surgery
(terminal ileum)
81% (77–86) 88% (82–91)
657Optimising monitoring in Crohn’s diseasesmall bowel involvement and to rule out complications
such as stenosing or penetrating disease, which may not be
detected by symptom assessment or endoscopy alone. A
systematic review of published studies calculated the spec-
ificity and sensitivity of MRI in the diagnosis of CD to be 78%
and 85%, respectively; corresponding values for ultrasonog-
raphy were 85% and 98%, respectively (Table 1).51 Theaccuracy of CT for CD diagnosis has not been robustly eval-
uated in prospective studies.51
A number of findings at MRI have been validated for the
diagnosis of active and severe CD, and quantitative indices
of activity have been developed to facilitate objective
interpretation of MR images.52,53 MR enterography is our
preferred modality for baseline assessment. It is accurate
Table 2 Summary of recommendations on monitoring for patients with Crohn's disease.
At diagnosis Symptomatic patient Asymptomatic patient Post-operative patient
Symptoms Perform in all patients:
Use standardised tool
(e.g. CDAI or HBI)
Perform 3–6 months after
commencing immunosuppressives
and 8–12 weeks after commencing
biologics:
Use standardised tool (e.g. CDAI or HBI)
Perform at each visit as part of global
assessment of remission:
Use standardised tool (e.g. CDAI or HBI)
Perform 3 months post surgery, every
3 months in the first year following
surgery and every 6–12 months
thereafter:
Use standardised tool (e.g. CDAI or HBI)
Endoscopy Perform in all patients:
Ileocolonoscopy+biopsies;
in specific patients, consider
upper-GI endoscopy, SBCE or
enteroscopy
Use precise standardised
descriptions of lesions
Perform when therapeutic decisions
are required:
Extent determined by known sites of
involvement and clinical presentation
Use precise standardised descriptions
of lesions
Perform if concerned about disease
progression or when therapeutic
decisions are required:
Ileocolonoscopy or upper-GI endoscopy
as appropriate
Use precise standardised descriptions
of lesions
Perform 6–12 months post surgery and
to confirm post-operative recurrence:
Ileocolonoscopy or capsule endoscopy
as appropriate
Use Rutgeerts score to measure
recurrence in neo-terminal ileum
Laboratory
parameters
Perform in all patients:
Complete blood count, liver
profile, albumin, iron studies,
renal function, CRP, faecal
calprotectin or lactoferrin
Perform when starting or switching
therapy and as required thereafter
according to disease severity,
treatment type and therapeutic
response:
Complete blood count, liver profile,
albumin, iron studies, renal
function, CRP, faecal calprotectin
or lactoferrin
Perform every 3–12 months as part of
the global assessment:
Complete blood count, liver profile,
albumin, iron studies, renal function,
CRP, faecal calprotectin or lactoferrin
Perform
3 months post-surgery, after the first
endoscopy, and every 3–6 months
thereafter:
Complete blood count, liver profile,
albumin, iron studies, renal function,
vitamin B12, CRP, faecal calprotectin
or lactoferrin
Imaging Perform in all patients:
To assess the extend and
severity of small bowel
involvement and presence
of complications
Use MR enterography or small
bowel ultrasonography
Perform prior to starting therapy,
particularly in high-risk patients:
To assess the extend and severity
of small bowel involvement and
presence of complications
Use MR enterography or small bowel
ultrasonography; limit CT use
Perform if there is concern about
disease progression or when new
therapeutic modifications are considered:
Use MRI or abdominal ultrasonography;
limit CT use
Perform when disease activity or structural
complications are suspected and
endoscopy is inconclusive or not available:
Use MR enterography, contrasted-enhanced
ultrasonography; limit CT use
CDAI, Crohn's disease Activity Index; CDEIS, Crohn's Disease Endoscopic Index of Severity; CRP, C-reactive protein, CT, computed tomography; GI, gastrointestinal; HBI, Harvey–Bradshaw
Index; IBDQ, Inflammatory Bowel Disease Questionnaire; MR, magnetic resonance; SBCE, small-bowel capsule endoscopy; SES-CD, Simple Endoscopic Score for Crohn's Disease.
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659Optimising monitoring in Crohn’s diseasefor establishing disease extent and severity,51,52,54 has been
shown to be as effective as endoscopy for diagnosis of
CD in some studies,55,56 and is superior to conventional
enteroclysis and small-bowel follow-through (SBFT).57 Ded-
icated small-bowel ultrasonography, a standard diagnostic
tool in many countries, may also be useful where expertise
exists.33 Small-bowel contrast-enhanced ultrasonography is
superior to plain abdominal ultrasound and SBFT in detecting
and documenting the extent of small-bowel lesions in CD.58
Contrast-enhanced pelvic MRI and/or rectal or transperineal
ultrasonography are advocated, in combination with exami-
nation under anaesthesia, to evaluate the anatomy, extent
and severity of perianal disease and detect perianal abscesses
needing urgent treatment.59 MRI can also evaluate fistula
anatomy and differentiate between simple and complex
fistulas, as well as determine therapeutic effect in fistulising
CD patients.60 Anorectal ultrasound can also detect lesions of
the internal and external anal sphincters, evaluate the
presence of interspincteric abscess and guide transcutaneous
drainage61; however, because of the discomfort associated
with this procedure, pelvic MRI is favoured where possible.3.2. Symptomatic patients
Routine monitoring of symptomatic patients is important to
optimise therapy and ensure adequate response. We advise
that symptoms are assessed at each visit, the frequency
of which will depend on disease severity, treatment and
response. Again, the consistent use of a standardised tool9–12
will likely help assessment of response to treatment. We
advocate that symptoms be re-evaluated 2–4 weeks after
initiating steroids, 3–6 months after initiating immunosup-
pressive therapy62 and 8–12 weeks after initiating biological
therapy.63 More frequent visits are recommended in patients
with moderate-to-severe disease to rule out deterioration of
the clinical condition. If a patient has symptoms that persist
despite treatment, further investigations should be performed
to rule out complications and reassess disease severity.
Objective evidence of inflammation is of utmost im-
portance in patients being considered for biological therapy.
In a post-hoc exploratory analysis of the SONIC study, which
compared infliximabmonotherapy, azathioprinemonotherapy,
and the two drugs combined in 508 adults with moderate-
to-severe CD who had not undergone previous immunosuppres-
sive or biologic therapy, the effects of infliximab were sig-
nificantly more pronounced in patients with elevated baseline
CRP levels, baseline mucosal lesions, and both elevated
baseline CRP levels and mucosal lesions.64 This underscores
the importance of endoscopic exploration or evaluation of
inflammatory biomarkers prior to starting treatment. SBCE or
enteroscopy may be considered to look for mucosal lesions in
patients with negative ileocolonoscopy and imaging evalua-
tions when objectively establishing the presence of disease
activity before the initiation of biological therapy.
While mucosal healing has been associated with improved
clinical outcomes in CD,3,65–68 there is a paucity of evidence
to guide endoscopic monitoring in symptomatic patients
during treatment. A poor correlation exists between endo-
scopic inflammation and symptom scores after steroid
treatment69; however, this correlation may be better with
biologic treatment.70 We suggest that endoscopy should beperformed to evaluate therapeutic response in patients with
persistent or recurrent symptoms despite therapy or more
globally when there is a doubt about disease control and
concern about disease progression. The extent of endoscopic
re-evaluation should be determined based upon known sites
of involvement and clinical presentation.
Our recommendation is that performance of a limited
number of laboratory investigations has value in the moni-
toring of symptomatic patients to assess disease activity
and exclude intercurrent infection. Prospective studies have
established the value of CRP as a marker of the presence and
severity of inflammatory activity,1,19,20,22,45,71–74 although it
should be noted that CRP may be normal in patients with
active CD.46 Furthermore, CRP may have a role in evaluating
response to therapy. For example, in CD patients treated
with anti-tumour necrosis factor (TNF) therapy, an elevated
baseline CRP has been shown to correlate with response75,76
and early normalisation of CRP levels predicts sustained
long-term response andmucosal healing.77 Faecal calprotectin
and, to a lesser degree, lactoferrin can be used to differentiate
between clinically active and inactive IBD, as well as estimate
the degree of mucosal inflammation, as they correlate better
with endoscopic inflammation than CRP or white blood cell
count.20,25,32,78–81 Faecal markers may also have a role in the
monitoring of therapeutic response: in clinical trials of CD
therapies, “normalisation” of faecal markers appeared to be a
useful and reliable surrogate for mucosal improvement and
healing.78,79 However, as with CRP, it should be noted that
faecal calprotectin and lactoferrin may be normal in patients
with clinically and endoscopically active CD, particularly ileal
disease.32 We advise that inflammatory markers should be
assessed to confirm active disease before starting or switching
therapy,64 with reassessment at intervals determined by
disease severity, treatment type and therapeutic response.
Symptomatic patients with small-bowel disease should
have small-bowel cross-sectional imaging prior to starting
therapy (and during therapy if they remain symptomatic) to
assess the activity of the disease and exclude complications.
Currently, the frequency of repeat imaging will depend on the
clinical circumstances. The optimum frequency of assessment
is unknown. For assessment of complications, plain radio-
graphs are useful in patients with severe or fulminant symp-
toms for detection of bowel obstruction, perforation or toxic
megacolon.82 Routine use of CT enterography should be avoid-
ed because of the radiation risk. However, contrast-enhanced
CT of the abdomen/pelvis or ultrasonography is useful and
necessary in acutely ill patients to rule out complications, such
as intra-abdominal abscess.83,84 MR enterography should be
used to assess the extent and severity of small-bowel disease.
MRI parameters have been found to correlate with acute
inflammatory score.85 Small-bowel ultrasonography may also
be useful, particularly in patients with disease located in the
terminal ileum.513.3. Asymptomatic patients
In asymptomatic patients, monitoring is needed to ensure
sustained control of inflammation beyond symptoms. Patients
in remission will typically visit the clinic every 3–6 months,
although patients with very indolent and stable disease may
only need to be seen every 12 months.
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assess remission at each visit.86 At the very least, the HBI
or another standardised symptom assessment tool should be
used to allow assessments to be longitudinally evaluated
using quantitative criteria.9–12
Endoscopy is invasive and is not typically used to assess
asymptomatic patients, other than when therapy cessation
is being considered after a long-term remission or when there
is discrepancy between symptoms and objective measures
of inflammation (e.g. elevated CRP or faecal calprotectin).
Endoscopic remission (CDEIS=0) was independently associated
with a more than two-fold reduction in risk of relapse in a
prospective study of infliximab withdrawal in 115 patients with
CDwho had been treated for at least 1 yearwith infliximab and
an antimetabolite and had been in corticosteroid-free remis-
sion for at least 6 months (hazard ratio 2.3; 95% CI 1.1–4.9; p=
0.04).87 Endoscopy (ileocolonoscopy in ileocolonic disease and
upper-GI endoscopy in patients with upper-GI involvement)
ought to be considered in asymptomatic patients when there is
concern about disease progression and when therapeutic
modifications are considered. Precise standardised description
of endoscopic lesions including type, location, depth and
extent is advocated.
We suggest that laboratory investigations form a routine
part of the global assessment at each visit in asymptomatic
patients. Complete blood count, liver profile and renal
function should be conducted every 3–12 months to monitor
treatment side effects. Monitoring CRP and faecal calprotectin
is a useful trigger for re-exploration by endoscopy and/or
cross-sectional imaging. CRP may be useful in predicting
short-term prognosis and relapse.21,88,89 The prognostic value
of stool markers to predict relapse is of major interest in view
of their correlation with endoscopic activity in CD,25,32 and
there is evidence to support the use of calprotectin and, to a
lesser degree, lactoferrin in this setting. In studies evaluating a
single faecal sample, calprotectin was a reliable predictor of
relapse in IBDwith colonic involvement over a 1-year follow-up
period.26,90–96 However the optimal cut-off threshold has not
yet been established and may depend on the clinical situation
and the desire to favour high sensitivity over high specificity or
vice versa. A continuous comparison between serial CRP values
should be performed in individual patients, with any increase
above previous values prompting further investigation for
possible relapse.
There are very few data evaluating cross-sectional
imaging in the asymptomatic CD patient. Our opinion is
that cross-sectional imaging may be appropriate in high-risk
patients when concern exists about disease progression,
there is a discrepancy between symptoms and inflammatory
biomarkers and when therapeutic modifications are being
considered. In this setting we advocate MR enterography or
abdominal ultrasonography, and the avoidance of repeat
exposure to ionising radiation.3.4. Post-operative patients
Recurrence following a resection for CD is common,18 with a
rate of endoscopic recurrence at the anastomosis of 65–90%
within 1 year of surgery.97–99 Monitoring is needed to detect
early recurrence and to identify complications. Although the
CDAI has been shown to have some value in identifyingpost-operative recurrence of CD,100 there are few data to
guide symptom assessment in post-operative patients. CD
symptoms should be assessed within 3 months of surgery,
preferably using the CDAI or HBI. Symptoms should continue
to be monitored regularly (e.g. every 3 months) in the first
year following surgery, then every 6–12 months thereafter,
depending on the risk of recurrence. It is important to note
that symptoms may be functionally derived, particularly in
the post-operative setting, highlighting the importance of
comprehensive monitoring of post-operative patients.
Disease often first recurs in the absence of symp-
toms,97,100,101 and symptoms associated with surgery,
particularly diarrhoea, may be misinterpreted as a manifes-
tation of disease recurrence. Therefore, the assessment of
objective parameters of inflammation is also required to
monitor for postoperative recurrence. Endoscopic recur-
rence precedes clinical recurrence and severe endoscopic
appearance predicts a poor prognosis.18 Ileocolonoscopy
should therefore be the gold-standard monitoring tool in this
setting to detect and define the presence and severity of
morphological recurrence. We consider that capsule endos-
copy is a potential alternative in selected patients who have
had mid-small bowel resections that are not evaluable by
ileocolonoscopy.42,102,103 The Rutgeerts score was developed
for lesions in the neoterminal ileum and at the ileocolonic
anastomosis and correlates with future clinical behaviour18;
we advocate its use for the assessment of recurrence in
the neoterminal ileum. Endoscopy should be performed
at 6–12 months following surgery, with the frequency of
further endoscopies depending on the findings of the first
evaluation and on the future disease course.
Very few studies have evaluated the use of biomarkers
in the post-operative setting, and there is no good corre-
lation between CRP (or erythrocyte sedimentation rate) and
endoscopy score for recurrence at 1 year.101 We propose
routine laboratory investigations during follow up after ileal
or colonic resections, including assessment of vitamin B12
levels, and CRP assessment every 3–6 months. Faecal
calprotectin and lactoferrin may have a role in predicting
early recurrence104–106; therefore, we propose that faecal
calprotectin is evaluated 3 months post surgery, with
consideration of an earlier endoscopy if an increase is
seen, and then after the first endoscopy as in the follow-up
of asymptomatic patients.
Cross-sectional imaging may be used where disease
activity or structural complications are suspected, and
where endoscopy is inconclusive. MR enterography,107 CT
enterography108 and contrast-enhanced ultrasonography109
may be used, with the frequency of imaging varying on a
case-by-case basis, although data are limited.4. Future directions
The opinions in this article are largely based on clinical
experience, given the current lack of integrated evidence to
guide optimal monitoring in CD, particularly with respect to
the most appropriate time points for using the available
tools in different patient scenarios.
There is a need for simple, reproducible scoring systems
and reading methodologies for endoscopy, and for further
training in this area. Refinement and validation of endoscopic
661Optimising monitoring in Crohn’s diseasecut-offs is another important area for future research;
currently, the level of tolerable mucosal ulceration and the
thresholds at which treatment should be intensified for
optimal clinical outcomes are unknown. Further validation of
non-endoscopic markers of disease activity and treatment
response is also awaited, as is the development and validation
of new biomarkers and other surrogates of endoscopy. In
addition, we need to standardise documentation for patients
with CD to allow ease of transfer between healthcare teams
and sites.
Available instruments measure disease activity at a fixed
point in time. The Lémann score, currently the subject of a
cross-sectional validation study, will enable the assessment
of cumulative structural damage to the bowel as measured
by appropriate imaging modalities and medical history. It
has potential for use initially within clinical studies to assess
the effect of therapies on the progression of bowel damage.
A number of ongoing clinical studies will provide further
data and assess the impact on clinical outcomes of a ‘tight
control’ approach to treatment, based around objective
parameters of inflammation. Long-term studies are needed
to define and validate the optimal treatment targets in CD.
There is much interest currently in the concept of ‘deep
remission’ (defined in the EXTEND study as combined
mucosal healing and symptomatic remission4) as a potential
treatment goal.5. Conclusions
The IBD Ahead 2011 programme has informed practice
guidance for the monitoring of patients with CD to facilitate
the achievement of tight disease control through sustained
control of inflammation in this progressive condition. Key
points include the need to measure and record baseline
parameters to enable subsequent tracking of disease activity
and progression of lesions; to adopt different approaches
in different patient scenarios; to regularly monitor disease
activity using objective markers of inflammation, rather
than relying on symptomatic assessment; to measure and
document precise and standardised descriptions of endo-
scopic lesions including type, location, depth and extent;
and to use cross-sectional imaging for complete assessment
of lesions where necessary, and for assessment of stenosing
and penetrating complications. We hope that this provides
helpful guidance to gastroenterologists in the monitoring of
CD within daily clinical practice.Disclosure
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Appendix A. IBD Ahead 2011 Statements on
the Optimal Monitoring of Crohn's Disease in
Clinical Practice
Approximately 600 gastroenterologists from 36 countries
participated in the IBD Ahead 2011 programme, which was
overseen by an International Steering Committee (ISC) made
up of gastroenterology specialists (members are listed in
Acknowledgements) and chaired by two authors of this
paper, Professor Colombel and Dr Panaccione. In addition,
each participating country had its own National Steering
Committee.
The programme took place between December 2010 and
September 2011 and consisted of several stages. Market
research identified key areas of uncertainty in the monitoring
of CD in clinical practice. The ISC then reviewed the data
collected to develop clinical questions relating to optimal
monitoring of CD patients in clinical practice. Feedback was
grouped into areas pertaining to: symptom assessment, endo-
scopic assessment, laboratory markers and cross-sectional
imaging. Five researchers (PP, AI, KK, HA and PM) were nom-
inated by the ISC to evaluate published evidence on CD
activity monitoring and develop answers to the clinical
questions. PubMed, Embase and the Cochrane Library were
searched using pre-defined search strings and limits, and
additional searches were conducted by hand as required. No
time limits were included in the search criteria. Abstracts from
the following conferences were searched: European Crohn's
and Colitis Organisation Congress 2010, 2011; Digestive Disease
Week 2010, 2011; and United European Gastroenterology
663Optimising monitoring in Crohn’s diseaseWeek 2009, 2010. National meetings were held to gather
expert opinion on the proposed answers. Where published
evidence was not available, experts provided best practice
guidance. Consolidated answers were generated and levels of
published evidence were assigned to each answer, according
to criteria from the University of Oxford Centre for Evidence
Based Medicine (http://www.cebm.net/index.aspx?o=1025).
An internationalmeeting was then held with experts from each
of the 36 participating countries. Participants voted on their
level of agreement with each answer using a scale of 1 to 9
(where 1=strong disagreement and 9=strong agreement). If
≥75% of participants scored within the 7–9 range, then the
answer was deemed to be agreed upon. If b75% of participants
scored within this range, the answer was debated and revised,
and a second vote was taken. Again, if ≥75% of participants
scored within the 7–9 range, the answer was deemed to be
agreed upon. If agreement was not reached at this stage, a
lack of agreement was noted. The results are noted below.
Statements on optimal monitoring of Crohn's
disease in clinical practice
1. Which assessments should be used at diagnosis?
1.a. Symptom monitoring1.a.1. The CDAI and HBI, as well as the IBDQ, are validated
tools for evaluating symptoms before patients enter
clinical trials9–12 (Level A) — 92% agreed.
1.a.2. In clinical practice, gastroenterologists rely on their
global clinical judgement when assessing symptoms;
assessments may be more comparable longitudinally
if the CDAI or HBI is used (Level D) — 90% agreed.
1.a.3 Symptom assessment tools should be used in all
patients to establish a baseline value for future
comparison (Level D) — 85% agreed.1.b Endoscopy
1.b.1 Ileocolonoscopy, with visualisation [precise description
of lesions], of the terminal ileum and all colonic
segments should be performed39–41 (Level A); at least
two biopsies of every segment and the rectum, including
areas that appear normal and abnormal, should be taken
to support diagnosis (Level D) — 85% agreed.
1.b.2. Upper GI endoscopy and biopsies are useful, particu-
larly in paediatric patients and in adult patients with
upper GI symptoms (Level D) — 90% agreed.
1.b.3. SBCE is recommended to support diagnosis in patients
with a high clinical suspicion of CD with inconclusive
ileocolonoscopy, gastroscopy and imaging evalua-
tions42,102 (Level B) — 88% agreed.
1.b.4. Enteroscopy is recommended when abnormalities
exist only in areas where traditional endoscopic
procedures for tissue biopsy are not possible (Level
D) — 87% agreed.
1.b.5. Precise standardised description of endoscopic lesions
including type, location, depth and extent is advocat-
ed (Level D). This may be achieved by utilising endo-
scopic scoring tools such as the CDEIS or the SES-CD —
86% agreed.
1.b.6. Endoscopy should be performed in all patients at
baseline to establish location, extent and severity of
disease (Level D) — 96% agreed.1.c Laboratory-based monitoring
1.c.1. Routine laboratory investigations should be con-
ducted, including complete blood count, liver profile,
albumin, iron studies, renal function and vitamin B12
(Level D) — 83% agreed.1.c.2. CRP should be assessed as a marker of inflammation
(Level D); patients with CD may have normal CRP
levels — 95% agreed.
1.c.3. Faecal calprotectin, and to a lesser degree lactoferrin,
can be assessed as a marker of intestinal inflammation
(Level B)17,21–24 to differentiate between intestinal
inflammation and IBS (Level B)24,28,30,31,48–50; stool
analysis and culture, and C. difficile toxin testing is also
recommended (Level D) — 90% agreed.
1.c.4. Routine laboratory and inflammatory marker assess-
ments should be conducted in all patients, where
available, to establish a baseline value for future
comparison (Level D) — 94% agreed.1.d. Cross-sectional imaging
1.d.1. MR enterography, where available, or CT if not, is
the recommended modality for baseline assessment
and should be used to assess the extent and severity
of disease (Level B)51,52,54–57,118–120; dedicated small
bowel ultrasonography may also be useful where
expertise exists (Level B)33,58; barium SBFT or
enteroclysis should be replaced by the above
modalities where available (Level D) — 86% agreed.
1.d.2. MRI, CT and/or ultrasound should be used to detect
and rule out disease complications49–53,55–60 (Level
B) — 88% agreed.
1.d.3. Baseline imaging should be performed in all patients
to assess the extent and severity of small bowel
involvement and to rule out complications such as
fibrostenosing or penetrating disease (Level D); the
choice of modality may be influenced by availability,
which could vary between countries (Level D) — 94%
agreed.2. Which assessments should be used in the symptomatic patient
and when should they be used?
2. Routine monitoring of patients through symptom assessment,
endoscopic evaluation, laboratory markers and imaging, is
important to ensure adequate response to therapeutic interven-
tions and to optimise therapy (Level D) — 94% agreed.
2.a. Symptom monitoring
2.a.1 The CDAI and HBI, as well as the IBDQ, are commonly
used in clinical trials, especially for establishing the
efficacy of pharmaceutical agents under investiga-
tion6,64,121 (Level A) — 90% agreed.
2.a.2. In clinical practice, gastroenterologists rely on
their global clinical judgement when assessing
symptoms; assessments may be more comparable
longitudinally if the CDAI or HBI is used (Level D) —
93% agreed.
2.a.3. In general, physicians should re-evaluate symp-
toms 2–4 weeks after initiating corticosteroids, 3–
6 months after initiating immunosuppressive ther-
apy, and 8–12 weeks after initiating biologic
therapy to establish therapeutic response (Level
D) — 89% agreed.
2.a.4. Symptoms that persist despite therapeutic inter-
vention should prompt further investigations to
rule out complications and reassess disease sever-
ity (Level D) — 99% agreed.
2.a.5. Symptoms should be assessed at each visit, the
frequency of which will be determined by disease
severity, treatment type and therapeutic response
(Level D) — 99% agreed.
2.b. Endoscopy
2.b.1 Mucosal healing has become an important therapeu-
tic goal (Level D) — 92% agreed.
2.b.2. Extent of endoscopic assessment should be deter-
mined by known sites of involvement and clinical
presentation (Level D) — 85% agreed.
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ered in patients with negative ileocolonoscopy and
imaging evaluations (Level D) — 84% agreed.
2.b.4. Precise standardised description of endoscopic
lesions including type, location, depth and extent
is advocated (Level D). This may be achieved by
utilising endoscopic scoring tools such as the CDEIS
and SES-CD — 94% agreed.
2.b.5. Endoscopic evaluation should be performed to
assess ongoing disease activity, especially when
other objective evidence of active disease is absent,
or to evaluate therapeutic response in patients with
persistent or recurrent symptoms despite therapy
(Level D) — 94% agreed.
2.b.6. There is insufficient evidence to recommend routine
repeat endoscopy in symptomatic patients; it should
be considered in patients in whom it will affect
further therapeutic decisions (Level D)— 96% agreed.
2.c. Laboratory-based monitoring
2.c.1. Laboratory investigations should be conducted in all
symptomatic patients to assess disease activity and
exclude intercurrent infection (Level D) — 95%
agreed.
2.c.2. CRP should be assessed as a marker of inflammation
in all symptomatic patients1,19,20,22,45,71–74 (Level A)
— 94% agreed.
2.c.3. Faecal calprotectin, and to a lesser degree lactofer-
rin, can be used as a marker of intestinal inflamma-
tion in symptomatic patients17,21,63–67 (Level B)— 90%
strongly agreed.
2.c.4. Inflammatory markers should be assessed to confirm
disease activity prior to starting or switching therapy
(Level D) — 95% agreed.
2.c.5. The frequency of reassessment of inflammatory
markers will be determined by disease severity,
treatment type and therapeutic response (Level D)
— 96% strongly agreed.
2.d. Cross-sectional imaging
2.d.1 MR enterography is the preferred mode to assess the
extent and severity of small bowel disease (Level
A)51,85; small bowel ultrasonography may also be
useful (Level B).51 Due to the radiation risks
associated with CT enterography, routine use is not
recommended (Level D) — 84% agreed.
2.d.2. A plain radiograph is useful in patients with severe
symptoms for the detection of bowel obstruction,
perforation or toxic colon distension (Level B)82 —
86% strongly agreed.
2.d.3. Contrast-enhanced CT of the abdomen/pelvis or
ultrasonography is useful in acutely ill patients to
rule out complications such as intra-abdominal
abscess83,84 (Level B) — 91% agreed.
2.d.4. Pelvic MRI (Level A) and/or transperineal (Level
C)60,122,123 and rectal ultrasonography (Level B)61
should be used to assess perianal disease and rule
out perianal abscess; imaging should be performed
in combination with examination under anaesthesia
(Level D) — 85% agreed.
2.d.5. Small-bowel imaging is recommended in symptom-
atic patients with small bowel disease prior to
starting therapy, especially in high-risk patients
where it can be used to monitor disease extent and
severity and therapeutic response (Level D) — 81%
agreed.
2.d.6. The frequency of imaging should be based on the
clinical situation; due to the radiation risks associ-
ated with CT enterography, its use should be limited
(Level D) — 99% agreed.3. Which assessments should be used in the asymptomatic patient
and when should they be used?
3. It is acknowledged that there is a disconnect between symptoms
and inflammatory disease activity; therefore, a strategy to
monitor disease beyond symptoms should be adopted, and may
include laboratory markers, endoscopy and imaging (Level D) —
98% agreed.
3.a. Symptom monitoring
3.a.1. The CDAI and HBI, as well as the IBDQ, are used for
monitoring patients participating in clinical trials,
who achieve remission (Level A)6,64,124 — 96%
agreed.
3.a.2. In clinical practice, gastroenterologists rely on their
global clinical judgement when assessing symptoms;
assessments may be more comparable longitudinally
if the CDAI or HBI is used (Level D) — 97% agreed.
3.a.3. Symptom assessment is part of a global approach to
assess remission at each visit86 (Level B) — 94%
agreed.
3.a.4. Symptoms should be assessed at each visit, the
frequency of which is dependent on the patient's
treatment regimen, but typically every 3–6 months
(Level D) — 82% agreed. [Note added in manuscript
development: Patients in remission will typically
visit the clinic every 3–6 months, although patients
with very indolent and stable disease may only need
to be seen every 12 months.]
3.b. Endoscopy
3.b.1 Ileocolonoscopy is recommended in ileocolonic dis-
ease; in patients with upper GI involvement, upper
GI endoscopy is recommended (Level D) — 89%
agreed.
3.b.2. Precise standardised description of endoscopic
lesions including type, location, depth and extent
is advocated (Level D). This may be achieved by
utilising endoscopic scoring tools such as the CDEIS
and SES-CD — 90% agreed.
3.b.3. Endoscopy in asymptomatic patients may be appro-
priate when there is concern about disease pro-
gression and when therapeutic modifications are
considered (Level D) — 88% agreed.
3.c. Laboratory-based monitoring
3.c.1. Laboratory investigations should be part of the
global assessment in an asymptomatic patient
(Level D) — 94% agreed.
3.c.2. CRP should be assessed as a marker of inflamma-
tion21,88,89 (Level A) — 97% agreed.
3.c.3. Faecal calprotectin (Level B) and lactoferrin (Level
C) can be assessed as markers of intestinal inflam-
mation (Level B)25,73–79 — 96% agreed.
3.c.4. Inflammatory markers should be assessed at each
visit (Level D) — 78% agreed.
3.c.5. Routine monitoring of inflammatory markers should
be performed on an individual basis and performed
every 3–12 months (Level D) — 94% agreed.
3.d. Cross-sectional imaging
3.d.1. MRI/enterography/enteroclysis or abdominal ultra-
sonography are preferred (Level D); repeated
exposure to ionising radiation should be avoided
(Level D) — 94% agreed. [Note added in manu-
script development: the authors concluded that MR
enteroclysis should not be advocated.]
3.d.2. Imaging in the asymptomatic patient may be
appropriate when there is concern about disease
progression and when therapeutic modifications are
considered (Level D) — 94% agreed.
4. Which assessments should be used in the post-operative patient
and when should they be used?
665Optimising monitoring in Crohn’s disease4.a. Symptom monitoring
4.a.1. It is acknowledged that disease may recur in the
absence of symptoms, and therefore symptoms alone
are inadequate when monitoring for post-operative
recurrence97,100,101 (Level A) — 97% agreed.
4.a.2. In clinical practice, gastroenterologists rely on their
global clinical judgement when assessing symptoms;
assessments may be more comparable longitudinally
if the CDAI or HBI is used (Level D) — 88% agreed.
4.a.3. Symptoms should be assessed within 3 months post
surgery (Level D) — 78% agreed.
4.a.4. Symptoms should be assessed regularly (for instance
every 3 months) in the first year after surgery, and
then every 6–12 months depending on the risk (Level
D) — 88% agreed.
4.b. Endoscopy
4.b.1. Ileocolonoscopy should be the standard-of-care
monitoring tool (Level B)39–41; capsule endoscopy
is a potential alternative in selected patients (Level
D) — 80% agreed.
4.b.2. Rutgeerts score should be used to assess recurrence
in the neo-terminal ileum (Level D) — 88% agreed.
4.b.3. Endoscopy should be performed 6–12 months after
surgery (Level D) — 89% agreed.
4.b.4. Endoscopy may be used to confirm the diagnosis of
post-operative recurrence by defining the presence
and severity of morphologic recurrence (Level B)18
— 93% agreed.
4.b.5. The frequency of further endoscopies depends on
the findings of the first endoscopy after surgery, and
on future disease course (Level D) — 91% agreed.
4.c. Laboratory-based markers
4.c.1. Routine laboratory investigations, including vitamin
B12 levels, should be conducted (Level D) — 91%
agreed.
4.c.2. CRP assessment should be conducted101 (Level C) —
87% agreed.
4.c.3. Faecal calprotectin and lactoferrin assessments may
be conducted104–106 (Level C) — 88% agreed.
4.c.4. Faecal calprotectin may identify patients with early
recurrence104–106 (Level C). This may be done at
3 months post surgery and after first endoscopy. CRP
may be measured at regular visits (Level D) — 96%
agreed.
4.c.5. As there is a disconnect between symptoms and
endoscopic disease activity, routine monitoring of
inflammatory markers every 3–6 months is recom-
mended (Level D) — 87% agreed.
4.d. Cross-sectional imaging
4.d.1. MR enterography(Level C), CT enterography (Level
C) and contrast-enhanced ultrasonography (Level C)
may be used49–53,55–60 — 87% agreed.
4.d.2. Imaging may be used when disease activity or
structural complications are suspected, and endoscopy
is inconclusive (Level D) — 93% agreed. [Note added in
manuscript development: the authors further refined
this statement to: Cross-sectional imagingmay be used
when disease activity or structural complications are
suspected, and endoscopy is inconclusive.]
4.d.3. The frequency of cross-sectional imaging should be
based on individual cases; due to the radiation risks
associated with CT enterography, routine use is not
recommended (Level D) — 97% agreed.
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